Advanced searches left 3/3

Ace Inhibitor - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 10 June 2022

* If you want to update the article please login/register

ACES - ACE Inhibitors Combined With Exercise for Seniors With Hypertension

"The aim of this study is to determine whether the choice of antihypertensive medications has an effect on changes in functional status and other cardiovascular risk factors among older people with hypertension. " Seniors with compromised function attend more CV activities, are at a greater risk of cardiac surgery, and a higher risk of CVD-related death than those with higher function. According to preliminary results, angiotensin converting enzyme inhibitors can help exercise-derived improvements in functional status among hypertensive seniors in comparison to other first-line antihypertensive agents. From two organizations to enroll in a longitudinal intervention study, sedentary men and women over 60 years of age with functional limitations and hypertension will be recruited from two locations. Note: Participants with a documented history of sensitivity to ACE inhibitors will be randomized 1:1 to one of the two other research products.

Source link: https://clinicaltrials.gov/ct2/show/NCT03295734


Risk of COVID 19 Disease Among Hypertensive Patients Using Angiotensin Converting Enzyme Inhibitors or Angiotensin Receptor Blockers At Assiut University Hospitals

"SARS-CORONA VIRUS -2 is an infectious disease caused by the SARS-CoV-2 virus. The virus can enters the body by either nose, eyes, or mouth. " In the altitudes, the spike protein binds specifically to the ACE2 receptors present on the type 2 pneumocytes. The virus enters the host cell either directly by membrane fusion or by endocytosis. The ACE inhibitors block angiotensin I from converting into angiotensin II. Following SARS infection, excessive activation of RAS and exacerbated pneumonia progression, the reason for this controversy lies in the fact that ACEIs and ARBs use may increase the expression of ACE2 receptor, the recognized cellular receptor and a crucial entry point for SARS-COV-2 infections. ACEI could be reduced by reducing the binding of ATII to angiotensin II and ARBs, reducing the conversion of angiotensin I to angiotensin II and ARBs, according to Bombardini et al. Reynolds et. al. al et. al : aristote Reynolds et. al. However, the optimal treatment for hypertension in COVID-19 patients is vague and remains to be clarified. "The aim of this observational study was to establish the connection between hypertensive patients using ACEI/ARBs and morbidity and mortality of COVID-19. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT05398731


Comparison Between the Efficacy of Sodium-Glucose Co-transporter 2 Inhibitor Therapy Versus Angiotensin-converting Enzyme Inhibitor in the Treatment of Diabetic Kidney Disease

"While there is one subgroup review in the CANVAS trial to determine the benefits of SGLT2 on patients who are on RAS blockers versus those without RAS blockers is negligible compared to the total number of participants. " The study contains two separate arms, non-inferiority RCT that compares the change in the eGFR rate after one year with ACEi and SGLT2i group in 212 men and non-pregnant women with DKD ages 30-65 years old with a UACR higher than 30 million ml/min/1. 73 million2. Mean change of the eGFR in the ACEi group is 5 ml/min/1. 73 million2 after one year, according to the study's findings. Rationale: SGLT2 inhibitors are recommended in patients with type 2 diabetes in patients with CKD to prevent CKD-related complications from progressing. The analysis of the CANVAS subgroup results shows that the results of SGLT2i in patients not on RAS inhibitors is high enough that the two arms, non-inferiority, will be ethically allowable. ".

Source link: https://clinicaltrials.gov/ct2/show/NCT05373004


A Dose Finding Trial for Angiotensin II in Hypertensive Adults on Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Anesthesia-Mediated Hypotension

"In reaction to this, it has become common practice to seek to maintain blood pressure levels in most patients under anesthesia at 20 percent of baseline. " The intravenous administration of Ang II may be a safe treatment of hypotension in this patient population, whether it be ACE inhibitors, ARBs, or other classes of antihypertensive agents, as well as determining the plasma concentrations of various RAAS components.

Source link: https://clinicaltrials.gov/ct2/show/NCT03733145

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions